Drreddys Laboratories | RDY - Operating Expenses


Drreddys Laboratories reported INR74.33B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Cipla INR 62.31B 3.04B Jun/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Drreddys Laboratories INR 74.33B 1.4B Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Novartis USD 10.2B 912M Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Phibro Animal Health USD 361.83M 29.47M Mar/2026
Prestige Brands USD 206.12M 5.17M Mar/2026
Richter Gedeon HUF 157.88B 6.77B Mar/2026
Sun Pharmaceuticals INR 117.43B 648.5M Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
Teva Pharmaceutical Industries USD 3.92B 691M Jun/2026